Analysts predict that Retrophin Inc (NASDAQ:RTRX) will announce sales of $36.71 million for the current quarter, according to Zacks. Two analysts have made estimates for Retrophin’s earnings. The lowest sales estimate is $36.2 million and the highest is $37.22 million. Retrophin posted sales of $33.31 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 10.2%. The firm is expected to issue its next quarterly earnings results on Thursday, August 3rd.

According to Zacks, analysts expect that Retrophin will report full-year sales of $36.71 million for the current financial year, with estimates ranging from $150.5 million to $151.11 million. For the next financial year, analysts anticipate that the company will post sales of $184.4 million per share, with estimates ranging from $184.19 million to $184.6 million. Zacks’ sales averages are an average based on a survey of research firms that cover Retrophin.

Retrophin (NASDAQ:RTRX) last posted its earnings results on Thursday, May 4th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.23. The firm had revenue of $33.62 million during the quarter, compared to analysts’ expectations of $36.20 million. Retrophin had a negative return on equity of 1.33% and a negative net margin of 32.96%. The firm’s revenue was up 15.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.14 earnings per share.

A number of research analysts have commented on RTRX shares. Zacks Investment Research raised Retrophin from a “hold” rating to a “strong-buy” rating and set a $24.00 target price on the stock in a report on Tuesday, March 7th. William Blair reaffirmed an “outperform” rating on shares of Retrophin in a report on Thursday, April 6th. Finally, BMO Capital Markets reduced their target price on Retrophin from $46.00 to $45.00 and set an “outperform” rating on the stock in a report on Thursday, March 2nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $32.25.

ILLEGAL ACTIVITY WARNING: “Analysts Anticipate Retrophin Inc (RTRX) Will Announce Quarterly Sales of $36.71 Million” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/06/16/analysts-anticipate-retrophin-inc-rtrx-will-announce-quarterly-sales-of-36-71-million-updated-updated-updated.html.

Retrophin (NASDAQ:RTRX) traded up 1.13% during midday trading on Thursday, reaching $17.91. The company had a trading volume of 193,475 shares. The firm’s market capitalization is $683.68 million. The firm’s 50-day moving average price is $18.31 and its 200 day moving average price is $19.44. Retrophin has a 12 month low of $15.40 and a 12 month high of $24.57.

Hedge funds have recently made changes to their positions in the company. Scopia Capital Management LP bought a new stake in shares of Retrophin during the third quarter valued at about $95,180,000. Consonance Capital Management LP increased its stake in shares of Retrophin by 14.3% in the third quarter. Consonance Capital Management LP now owns 3,084,947 shares of the biopharmaceutical company’s stock valued at $69,041,000 after buying an additional 385,000 shares during the period. Perceptive Advisors LLC increased its stake in shares of Retrophin by 4.5% in the first quarter. Perceptive Advisors LLC now owns 2,807,525 shares of the biopharmaceutical company’s stock valued at $51,826,000 after buying an additional 120,113 shares during the period. FMR LLC increased its stake in shares of Retrophin by 24.8% in the first quarter. FMR LLC now owns 1,958,875 shares of the biopharmaceutical company’s stock valued at $36,161,000 after buying an additional 389,714 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Retrophin by 7.3% in the first quarter. Vanguard Group Inc. now owns 1,509,539 shares of the biopharmaceutical company’s stock valued at $27,866,000 after buying an additional 102,833 shares during the period.

About Retrophin

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

5 Day Chart for NASDAQ:RTRX

Get a free copy of the Zacks research report on Retrophin (RTRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Retrophin Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc and related stocks with our FREE daily email newsletter.